“My Prostate Is Too Big for Surgery”
Usually that means too big for one specific treatment. Size closes some doors and opens others — it should not leave you with nothing but open surgery or a catheter.
Find out in under a minute – no phone call needed.
On this page
Being told your prostate is too large for the treatment you wanted is usually accurate about that treatment and misleading about your options. Size closes some doors and opens others. The one thing it should not do is leave you with nothing but open surgery or a permanent catheter.
What Counts as Too Big
Prostate volume is measured in millilitres or grams — the numbers are used interchangeably. A normal gland in a man in his fifties averages around 24 mL, rising to roughly 38 mL by his late seventies. Commonly used bands put mild enlargement at 30–50 mL, moderate at 50–80 mL, and large above 80 mL.
That 80 mL mark is where treatment options start falling away, which is why you hear it so often. It is not a biological threshold. It is the point beyond which most of the minimally invasive devices were never studied.
What a Large Gland Rules Out
- UroLift is designed for glands generally under 80 mL. Above that, there is too much tissue for implants to retract usefully.
- Rezum was studied mainly between 30 and 80 mL. It is used above that, but a four-year analysis found men with 80–120 g glands needed retreatment significantly more often — 15.2% — than men with smaller prostates.
- TURP becomes progressively harder as the gland grows. Longer resection means more bleeding and more fluid absorption, which is why it has traditionally been avoided in very large glands.
So the phrase “too big” is usually shorthand for “too big for the specific thing I was going to offer you.” That is a real constraint, and it is not the same as running out of treatments.
What Is Left
Two categories remain, and they are genuinely different from one another.
HoLEP and simple prostatectomy
HoLEP enucleates the whole obstructing adenoma and works at any gland size. It is the most durable option available and the standard choice for men at high bleeding risk. Simple prostatectomy — open, laparoscopic, or robotic — removes the adenoma surgically and has historically been the preferred approach above 80 cc. Both are effective. Both involve general anesthesia, and both carry a significant risk of retrograde ejaculation.
PAE
Works through the arteries rather than the urethra, so gland size does not create the same technical problem. There is no practical upper limit, and unlike the transurethral devices it has published outcomes in genuinely enormous prostates. It is done under local anesthetic with sedation, as an outpatient, and it preserves ejaculation.
The honest counterweight: PAE is less durable than enucleation. Roughly 16–21% of men need a further prostatic procedure within five years. For a large gland, the choice is essentially between the most definitive option with an operation and a recovery, or a same-day procedure that preserves function and accepts a higher chance of needing more later.
Very Large and Giant Glands
Above roughly 200 mL — sometimes called giant prostatic hyperplasia — many men are poor candidates for surgery on grounds of technical difficulty, blood loss, or their own general health. This is the group most often told there is nothing straightforward to offer.
There is published PAE data specifically in this population. In a series of men with glands above 200 mL and severe symptoms, mean IPSS fell from 26.5 before treatment to 18.0 at twelve months and 10.5 at twenty-four months. Mean prostate volume fell from 303 mL to 258 mL and then 209 mL, peak flow roughly doubled, and post-void residual dropped substantially.
Read those numbers carefully, because they show something useful. The gland stayed large — 209 mL is still an enormous prostate. But symptoms moved from severe to mild. That is the point worth internalising about PAE in big glands: the goal is not to make the prostate normal-sized. It is to reduce it enough that it stops obstructing.
Very large glands do come with a caution: shrinkage takes longer and the chance of needing a second treatment is higher. Anyone offering PAE for a 250 mL prostate should be saying so plainly at the outset.
When Surgery Is the Problem, Not the Size
Sometimes the barrier is not the prostate at all. Men are turned down for BPH surgery because of heart or lung disease, frailty, anticoagulation that cannot safely be stopped, or a general anesthetic that is considered too risky.
PAE is often workable in exactly these circumstances. It uses local anesthetic and sedation rather than a general, it is done through a pinhole in the wrist or groin, and anticoagulation can usually be managed with coordinated planning instead of a prolonged interruption. For a man on a catheter who has been told he is not fit for an operation, this is worth a second opinion rather than acceptance — in one large series, 94% of men who came to PAE in urinary retention were catheter-free three months afterwards.
Where Prostate Artery Embolization Fits
PAE treats an enlarged prostate from the inside of the blood vessels rather than through the urethra. A catheter is threaded from a pinhole in the wrist or groin to the small arteries feeding the prostate, and microscopic particles are released to reduce its blood supply. The gland shrinks over the following months and the pressure on the urethra eases. There is no incision, no general anesthetic, no instrument passed through the penis, and no overnight stay.
Because it works through the arteries instead of the prostatic urethra, PAE avoids the bladder neck entirely. That anatomical difference is why it behaves so differently from the transurethral procedures on the one measure men care about most and are least often asked about.
That last figure belongs here rather than buried. PAE trades durability for safety and functional preservation. Around one man in five needs something further within five years, against a much lower rate after resective surgery. In the largest long-term series, 88% of men had still avoided prostatectomy at five years, and a repeat PAE kept most of those who needed more treatment out of surgery altogether. Whether that trade is worth it depends on what you are optimising for, and it is a legitimate reason some men choose TURP or HoLEP instead.
PAE entered the American Urological Association guideline in the 2023 amendment, and the European Association of Urology guideline the same year. The previous AUA guideline had recommended against it outside clinical trials, so this is a genuine change in standing rather than marketing language — and it is the reason insurance coverage has improved. Our insurance page covers how we handle authorisation, and the office can check your benefits directly.
California Prostate Center
Atabak Allaei, MD
- Double board-certified in Vascular & Interventional Radiology and Diagnostic Radiology
- Attending staff at Cedars-Sinai Medical Center and UCI Health
- More than 10,000 image-guided procedures performed
- Focused practice in prostate artery embolization, including large glands and men who are poor candidates for surgery
Common Questions
Is a 100 gram prostate too big for treatment?
No. It is too big for UroLift and beyond the range Rezum was chiefly studied in, but HoLEP, simple prostatectomy, and PAE all handle glands of that size. PAE has published outcomes well above 200 mL.
What is the largest prostate PAE can treat?
There is no fixed ceiling. Published series include men with glands above 200 mL, in whom symptoms improved from severe to mild over two years even though the prostate remained large. Very large glands take longer to respond and carry a higher chance of needing a second treatment.
Does the prostate have to become normal size for symptoms to improve?
No, and this is a common misunderstanding. Symptom relief tracks the reduction in obstruction rather than the final volume. In the giant prostate series, mean volume fell from about 303 mL to 209 mL while mean symptom scores fell from severe to mild.
I was told I am not healthy enough for prostate surgery. Is PAE possible?
Often, yes. PAE avoids general anesthesia, needs only a pinhole arterial access, and anticoagulation can usually be managed with planning rather than a long interruption. Men judged unfit for an operation are a group specifically worth evaluating for it.
Is HoLEP better than PAE for a large prostate?
HoLEP is more durable and works at any size, which is a genuine advantage. It also requires general anesthesia and carries a significant risk of retrograde ejaculation. PAE is same-day, preserves ejaculation, and suits men who cannot have surgery, at the cost of a higher chance of needing further treatment. Which is better depends on what you are optimising for.
References
- Prostate artery embolization has long-term efficacy for treatment of severe lower urinary tract symptoms from giant prostatic hyperplasia. Mean IPSS 26.5 to 18.0 to 10.5; mean prostate volume 303 to 258 to 209 mL at baseline, 12 and 24 months.
- Prostatic Artery Embolization: Mid- to Long-Term Outcomes in 1,075 Patients. 94% of the retention cohort catheter-free at 3 months; 16% required reintervention up to 60 months; severe adverse events 0.65%.
- A comparative analysis of Rezum outcomes based on prostate size: four-year retrospective analysis. Retreatment 15.2% in the 80–120 g group. Simple prostatectomy historically preferred above 80 cc.
- Berges R, Oelke M. Age-stratified normal values for prostate volume, PSA, maximum urinary flow rate and IPSS. World J Urol. 2011;29(2):171–178. Mean total prostate volume 24 to 38 cc across ages 50 to 80.
- Bilhim T, et al. Long-Term PAE Results. Reintervention 21% at 5 years; freedom from prostatectomy 88% at 5 years.
This article is for general education and does not replace an evaluation by a qualified physician. Individual results vary. See our disclaimer.
Find out whether PAE fits your prostate
Dr. Allaei reviews your imaging, PSA and symptom scores himself and tells you plainly whether embolization suits your anatomy, what to expect, and when another treatment is the better answer.
